Intravitreal Bevacizumab for diabetic retinopathy

J. Fernando Arevalo, Rafael A. Garcia-Amaris

Research output: Contribution to journalReview articlepeer-review

51 Scopus citations


Diabetic retinopathy (DR) remains the major threat to sight in the working age population. Diabetic macular edema (DME) is a manifestation of DR that produces loss of central vision. Macular edema within 1 disk diameter of the fovea is present in 9% of the diabetic population. Proliferative diabetic retinopathy (PDR) is a major cause of visual loss in diabetic patients. In PDR, the growth of new vessels from the retina or optic nerve, is thought to occur as a result of vascular endothelial growth factor (VEGF) release into the vitreous cavity as a response to ischemia. Furthermore, VEGF increases vessel permeability leading to deposition of proteins in the interstitium that facilitate the process of angiogenesis and macular edema. This review demonstrates multiple benefits of intravitreal bevacizumab on DR including DME and PDR. The results indicate that intravitreal bevacizumab injections may have a beneficial effect on macular thickness and visual acuity (VA), independent of the type of macular edema that is present. Therefore, in the future this new treatment modality could replace or complement focal/ grid laser photocoagulation in DME. In addition, in PDR, this new option could be an adjuvant agent to PRP so that more selective therapy may be applied.

Original languageEnglish (US)
Pages (from-to)39-46
Number of pages8
JournalCurrent diabetes reviews
Issue number1
StatePublished - 2009
Externally publishedYes


  • Diabetic macular edema
  • Intravitreal bevacizumab
  • Panretinal photocoagulation
  • Proliferative diabetic retinopathy
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Intravitreal Bevacizumab for diabetic retinopathy'. Together they form a unique fingerprint.

Cite this